VIVUS Reports Third Quarter 2015 Financial Results
Get Alerts VVUS Hot Sheet
Join SI Premium – FREE
MOUNTAIN VIEW, CA -- (Marketwired) -- 11/04/15 -- VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health, today provided a business update and reported its financial results for the third quarter ended September 30, 2015.
"The U.S. market for branded anti-obesity pharmacotherapeutics continues to develop at a substantially lower rate than expected, held in check by a number of factors," said Seth H. Z. Fischer, CEO. "We watched this trend closely while controlling our costs during the first half of 2015. In August 2015, we reduced our Qsymia sales force to fifty territories and further streamlined our headquarters staff. The objective of this restructuring was to align our resources with obesity market realities and the opportunity as it currently exists, and to bring VIVUS closer to achieving neutral or positive operating cash flows by year-end 2016. Going forward, we will continue to monitor market conditions for any positive developments with physicians, payors, and patients that may indicate an increased investment is warranted."
Mr. Fischer continued, "We are working with leading cardiovascular outcome trial experts in planning substantial revisions to the original design and execution of the FDA-required Qsymia cardiovascular outcomes trial (CVOT) known as AQCLAIM, with the goal of reducing costs while also fulfilling the requirement of further demonstrating the long-term cardiovascular safety of Qsymia. We met earlier this year with the FDA to provide a CVOT program update. This dialog is ongoing, and we are committed to involving the FDA in reviewing alternative proposals that will satisfy the requirements."
VIVUS is actively pursuing a commercial partnership for avanafil in Latin America, and the Company plans to make an announcement as soon as an alliance is secured. VIVUS is pleased with the plans being executed currently by its STENDRA® and SPEDRA™ commercialization partners to promote the 15-minute onset of action data as a key component of their promotional campaigns.
Third Quarter 2015 Financial Results
Total revenue was $24.9 million in the current quarter, compared to $33.9 million in the third quarter of 2014. Net product revenue was $14.0 million from sales of Qsymia in the current quarter, compared to $12.5 million in the third quarter of 2014. Under our commercialization agreements for STENDRA® or SPEDRA™, we recognized $10.0 million in supply revenue in the current quarter, compared to $5.3 million in the third quarter of 2014. We also recognized $0.9 million in royalty revenue in the current quarter, compared to $1.1 million in the third quarter of 2014.
Approximately 146,000 Qsymia prescriptions were dispensed in the current quarter, compared to 140,000 in the third quarter of 2014.
Total cost of goods sold, excluding inventory impairment, was $11.8 million in the current quarter, compared to $7.3 million in the third quarter of 2014. The increase was due primarily to the cost of STENDRA supply in proportion to the increase in supply revenue.
Total selling, general and administrative expense was $17.1 million in the current quarter, compared to $27.8 million in the third quarter of 2014. Selling and marketing expense for the commercialization of Qsymia totaled $11.0 million in the current quarter, compared to $18.4 million in the third quarter of 2014. The total decrease was due primarily to the realignment of our sales force, refinement of our marketing and promotional programs, and continued cost cutting initiatives.
Total research and development expense was $1.5 million in the current quarter, compared to $2.6 million in the third quarter of 2014. The fluctuation was due primarily to the timing of clinical projects.
Charges incurred for severance were approximately $2.5 million in the current quarter, related to our restructuring plan initiated in July 2015. Annual savings from this restructuring are expected to be approximately $14.4 million beginning in year 2016.
Net loss was $16.1 million, or $0.15 net loss per share, in the current quarter, compared to a net loss of $15.8 million, or $0.15 net loss per share, in the third quarter of 2014.
Cash, Cash Equivalents and Available-for-Sale Securities
Cash, cash equivalents and available-for-sale securities (collectively cash) totaled $251.1 million at September 30, 2015, as compared to $299.6 million at December 31, 2014. The decrease was due primarily to cash used in operating activities and repayment of debt.
Recent Business Update
In July 2015, we initiated a specialty sales force co-promotion pilot program with Kadmon Corporation intended to introduce Qsymia to liver disease specialists. This pilot program will be evaluated at year-end 2015.
Note to Investors
As previously announced, VIVUS will hold a conference call and an audio webcast to discuss the third quarter ended September 30, 2015 financial results today, November 4, 2015, beginning at 4:30PM Eastern Time. Investors may listen to this call by dialing toll-free (877) 359-2916 in the U.S. and (224) 357-2386 from outside the U.S. A webcast replay will be available for 30 days and may be accessed at http://ir.vivus.com/.
About Qsymia
Qsymia is approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol.
The effect of Qsymia on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of Qsymia in combination with other products intended for weight loss, including prescription and over-the-counter drugs, and herbal preparations, have not been established.
Important Safety Information
Qsymia® (phentermine and topiramate extended-release) capsules CIV is contraindicated in pregnancy; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors (MAOIs); or in patients with hypersensitivity to sympathomimetic amines, topiramate, or any of the inactive ingredients in Qsymia.
Qsymia can cause fetal harm. Females of reproductive potential should have a negative pregnancy test before treatment and monthly thereafter and use effective contraception consistently during Qsymia therapy. If a patient becomes pregnant while taking Qsymia, treatment should be discontinued immediately, and the patient should be informed of the potential hazard to the fetus.
The most commonly observed side effects in controlled clinical studies, 5% or greater and at least 1.5 times placebo, include paraesthesia, dizziness, dysgeusia, insomnia, constipation, and dry mouth.
About Avanafil
STENDRA® (avanafil) is approved in the U.S. by the FDA for the treatment of erectile dysfunction. Auxilium Pharmaceuticals, Inc. has exclusive marketing rights to STENDRA in the U.S. and Canada. In January 2015, Auxilium was purchased by Endo International, plc., or Endo.
STENDRA is available through retail and mail order pharmacies. Endo currently offers programs that help patients with out-of-pocket costs.
SPEDRA™, the trade name for avanafil in the EU, is approved by the EMA for the treatment of erectile dysfunction in the EU. VIVUS has granted an exclusive license to the Menarini Group through its subsidiary Berlin-Chemie AG to commercialize and promote SPEDRA for the treatment of erectile dysfunction in over 40 European countries plus Australia and New Zealand.
VIVUS has granted an exclusive license to Sanofi to commercialize avanafil in Africa, the Middle East, Turkey, and the Commonwealth of Independent States (CIS) including Russia.
Avanafil is licensed from Mitsubishi Tanabe Pharma Corporation (MTPC). VIVUS owns worldwide development and commercial rights to avanafil for the treatment of sexual dysfunction, with the exception of certain Asian-Pacific Rim countries. VIVUS is in discussions with other parties for the commercialization rights to its remaining territories.
For more information about STENDRA, please visit www.Stendra.com.
Important Safety Information
STENDRA® (avanafil) is prescribed to treat erectile dysfunction (ED).
Do not take STENDRA if you take nitrates, often prescribed for chest pain, as this may cause a sudden, unsafe drop in blood pressure.
Discuss your general health status with your healthcare provider to ensure that you are healthy enough to engage in sexual activity. If you experience chest pain, nausea, or any other discomforts during sex, seek immediate medical help.
STENDRA may affect the way other medicines work. Tell your healthcare provider if you take any of the following; medicines called HIV protease inhibitors, such as ritonavir (Norvir®), indinavir (Crixivan®), saquinavir (Fortavase® or Invirase®) or atazanavir (Reyataz®); some types of oral antifungal medicines, such as ketoconazole (Nizoral®), and itraconazole (Sporanox®); or some types of antibiotics, such as clarithromycin (Biaxin®), telithromycin (Ketek®), or erythromycin.
In the rare event of an erection lasting more than 4 hours, seek immediate medical help to avoid long-term injury.
In rare instances, men taking PDE5 inhibitors (oral erectile dysfunction medicines, including STENDRA) reported a sudden decrease or loss of vision. It is not possible to determine whether these events are related directly to these medicines or to other factors. If you experience sudden decrease or loss of vision, stop taking PDE5 inhibitors, including STENDRA, and call a doctor right away.
Sudden decrease or loss of hearing has been rarely reported in people taking PDE5 inhibitors, including STENDRA. It is not possible to determine whether these events are related directly to the PDE5 inhibitors or to other factors. If you experience sudden decrease or loss of hearing, stop taking STENDRA and contact a doctor right away. If you have prostate problems or high blood pressure for which you take medicines called alpha blockers or other anti-hypertensives, your doctor may start you on a lower dose of STENDRA.
Drinking too much alcohol when taking STENDRA may lead to headache, dizziness, and lower blood pressure.
STENDRA in combination with other treatments for ED is not recommended.
STENDRA does not protect against sexually transmitted diseases, including HIV.
The most common side effects of STENDRA are headache, flushing, runny nose and congestion.
Please see full patient prescribing information for STENDRA (50 mg, 100 mg, 200 mg) tablets.
About VIVUS
VIVUS is a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health. For more information about the company, please visit www.vivus.com.
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to risks, uncertainties and other factors, including risks and uncertainties related to our ability to eliminate expenses and reduce our headcount and fully realize the benefits from a corporate restructuring to achieve neutral or positive operating cash flows by year-end 2016, including the timing thereof; risks and uncertainties related to the impact of lower annual net cost savings than currently expected; risks and uncertainties related to the impact of a corporate restructuring on our business and unanticipated charges not currently contemplated that may occur as a result of a corporate restructuring; risks and uncertainties related to our ability to accurately forecast Qsymia demand and inventory requirements, including the impact of a corporate restructuring on our future sales forecast and inventory; risks and uncertainties related to our ability to work with leading cardiovascular outcome trial experts in planning substantial revisions to the original design and execution of the CVOT with the goal of reducing costs and obtaining FDA agreement that the revised CVOT would fulfill the requirement of demonstrating the long-term cardiovascular safety of Qsymia; and risks and uncertainties related to our ability to successfully complete on acceptable terms, and on a timely basis, avanafil partnering discussions for other territories under our license with MTPC in which we do not have a commercial collaboration, including Latin America. These risks and uncertainties could cause actual results to differ materially from those referred to in these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. Investors should read the risk factors set forth in VIVUS's Form 10-K for the year ended December 31, 2014 as filed on February 25, 2015 and as amended by the Form 10-K/A filed on April 30, 2015, and periodic reports filed with the Securities and Exchange Commission. VIVUS does not undertake an obligation to update or revise any forward-looking statements.
VIVUS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share data) (Unaudited) Three Months Ended Nine Months Ended September 30, September 30, --------------------- --------------------- 2015 2014 2015 2014 ---------- ---------- ---------- ---------- Revenue: Net product revenue $ 14,011 $ 12,454 $ 40,652 $ 32,575 License and milestone revenue - 15,070 11,574 38,614 Supply revenue 10,056 5,300 26,651 18,336 Royalty revenue 869 1,053 1,210 2,924 ---------- ---------- ---------- ---------- Total revenue 24,936 33,877 80,087 92,449 ---------- ---------- ---------- ---------- Operating expenses: Cost of goods sold 11,765 7,268 31,531 23,816 Selling, general and administrative 17,129 27,828 65,730 84,703 Research and development 1,532 2,574 6,825 11,083 Inventory impairment and other non-recurring charges 2,539 4,119 32,061 6,173 ---------- ---------- ---------- ---------- Total operating expenses 32,965 41,789 136,147 125,775 ---------- ---------- ---------- ---------- Loss from operations (8,029) (7,912) (56,060) (33,326) Interest expense and other expense, net 8,076 8,135 24,851 24,534 ---------- ---------- ---------- ---------- Loss before income taxes (16,105) (16,047) (80,911) (57,860) Provision for (benefit from) income taxes 1 (222) 13 (660) ---------- ---------- ---------- ---------- Net loss $ (16,106) $ (15,825) $ (80,924) $ (57,200) ========== ========== ========== ========== Basic and diluted net loss per share $ (0.15) $ (0.15) $ (0.78) $ (0.55) ========== ========== ========== ========== Shares used in per share computation: Basic and diluted 104,014 103,477 103,950 103,373 ========== ========== ========== ==========
VIVUS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) September 30, December 31, 2015 2014* -------------- -------------- ASSETS (Unaudited) Current assets: Cash and cash equivalents $ 79,496 $ 83,174 Available-for-sale securities 171,591 216,397 Accounts receivable, net 14,894 11,595 Inventories 9,228 34,447 Prepaid expenses and other assets 9,640 12,824 -------------- -------------- Total current assets 284,849 358,437 Property and equipment, net 1,121 1,346 Non-current assets 5,288 7,155 -------------- -------------- Total assets $ 291,258 $ 366,938 ============== ============== LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 7,522 $ 10,430 Accrued and other liabilities 14,821 17,037 Deferred revenue 21,978 19,445 Current portion of long-term debt 15,080 10,459 -------------- -------------- Total current liabilities 59,401 57,371 Long-term debt, net of current portion 219,166 217,324 Deferred revenue, net of current portion 7,124 8,876 Non-current accrued and other liabilities 692 849 -------------- -------------- Total liabilities 286,383 284,420 -------------- -------------- Commitments and contingencies Stockholders' equity: Common stock and additional paid-in capital 828,952 825,795 Accumulated other comprehensive (loss) income 96 (28) Accumulated deficit (824,173) (743,249) -------------- -------------- Total stockholders' equity 4,875 82,518 -------------- -------------- Total liabilities and stockholders' equity $ 291,258 $ 366,938 ============== ==============
* The Condensed Consolidated Balance Sheet at December 31, 2014 has been derived from the Company's audited financial statements at that date.
VIVUS, Inc.Dana B. ShinbaumCorporate Development & Investor [email protected] Investor Relations: The Trout GroupBrian KorbManaging [email protected]
Source: VIVUS, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fisker (FSR) files form 10-K, sees more job cuts, reiterates going concern doubts
- Renasant Corp. (RNST) Appoints Kevin D. Chapman as Next CEO
- KKR Real Estate Finance Trust (KREF) Tops Q1 EPS by 4c
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!